Although targeting CGRP and its receptor with antibodies and antagonists was a breakthrough in migraine treatment, it is too early to assess the safety of long-term anti-CGRP treatment and these therapeutics might not be universal cure-all compounds as some patients do not show a satisfactory response [11, 12]. The gene discussed is CALCA; the disease is migraine disorder.